AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
AMGEN INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$424.94−7.55 (-1.75%)
Close on Oct 19, 2026
- Market cap
- $231.17B
- P/E (TTM)
- 26.4
- Dividend yield
- 2.27%
AMGEN INC revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product sales | $36.26B | $35.49B | $35.15B | $34.50B | $33.51B | $32.78B | $32.03B | $31.14B | $29.54B | $28.18B | $26.91B | $25.63B | 95.2% | +8.2% |
| Other products | $7.15B | $6.83B | $7.26B | $6.28B | $5.79B | $5.73B | $5.63B | $5.44B | $5.08B | $4.90B | $4.70B | $3.34B | 18.8% | +23.6% |
| Prolia | $3.68B | $4.04B | $4.41B | $4.53B | $4.43B | $4.47B | $4.37B | $4.32B | $4.26B | $4.12B | $4.05B | $3.93B | 9.7% | -17.0% |
| EVENITY | $2.42B | $2.22B | $2.10B | $1.93B | $1.79B | $1.66B | $1.56B | $1.45B | $1.36B | $1.25B | $1.16B | $1.07B | 6.3% | +35.0% |
| Otezla | $2.13B | $2.26B | $2.27B | $2.26B | $2.24B | $2.17B | $2.13B | $2.13B | $2.13B | $2.19B | $2.19B | $2.18B | 5.6% | -4.9% |
| TEPEZZA | $2.08B | $2.01B | $1.90B | $1.91B | $1.83B | $1.81B | $1.85B | $1.84B | $1.35B | $872.00M | $448.00M | – | 5.5% | +13.6% |
| ENBREL | $2.01B | $2.04B | $2.23B | $2.71B | $2.95B | $3.26B | $3.32B | $3.32B | $3.53B | $3.69B | $3.70B | $3.78B | 5.3% | -31.9% |
| Other revenues | $1.84B | $1.73B | $1.60B | $1.47B | $1.41B | $1.35B | $1.40B | $1.39B | $1.39B | $1.35B | $1.28B | $1.20B | 4.8% | +30.6% |
| XGEVA | $1.75B | $1.93B | $2.08B | $2.20B | $2.20B | $2.23B | $2.23B | $2.19B | $2.17B | $2.14B | $2.11B | $2.07B | 4.6% | -20.5% |
| BLINCYTO | $1.69B | $1.60B | $1.56B | $1.53B | $1.46B | $1.34B | $1.22B | $1.08B | $969.00M | $911.00M | $861.00M | – | 4.4% | +15.7% |
| Nplate | $1.68B | $1.62B | $1.52B | $1.48B | $1.48B | $1.45B | $1.46B | $1.51B | $1.47B | $1.43B | $1.48B | $1.56B | 4.4% | +14.2% |
| TEZSPIRE | $1.68B | $1.54B | $1.48B | $1.30B | $1.19B | $1.08B | $972.00M | $853.00M | $745.00M | $644.00M | $567.00M | – | 4.4% | +40.9% |
| KRYSTEXXA | $1.41B | $1.36B | $1.34B | $1.25B | $1.24B | $1.19B | $1.19B | $1.11B | $801.00M | $507.00M | $272.00M | – | 3.7% | +13.6% |
| Aranesp | $1.35B | $1.36B | $1.39B | $1.36B | $1.34B | $1.33B | $1.34B | $1.35B | $1.34B | $1.36B | $1.36B | $1.39B | 3.6% | +0.7% |
| Vectibix | $1.23B | $1.20B | $1.18B | $1.10B | $1.10B | $1.07B | $1.05B | $1.05B | $1.02B | $998.00M | $984.00M | – | 3.2% | +11.6% |
| KYPROLIS | – | – | – | $1.43B | $1.45B | $1.45B | $1.50B | $1.48B | $1.45B | $1.42B | $1.40B | $1.38B | – | – |
| Repatha | – | – | – | $2.75B | $2.53B | $2.36B | $2.22B | $2.03B | $1.87B | $1.76B | $1.64B | $1.55B | – | – |
By region
From the segment and revenue-disaggregation notes of Amgen's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.